We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

601375:SSECentral China Securities Co Ltd Class A Analysis

Data as of 2026-06-22 - not real-time

CN¥4.13

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Central China Securities is trading at CNY 4.13, comfortably above its 20‑day SMA (3.97) and 50‑day SMA (4.00) but still below the 200‑day SMA (4.31), indicating short‑term momentum while the longer‑term trend remains bearish. The MACD histogram is positive (0.019) and the signal line is bearish, suggesting a modest near‑term upside, yet the RSI of 57 points to neutral momentum. Volatility is high at 31% over the past 30 days, but the stock’s beta of 0.51 signals lower market‑wide risk. Valuation is mixed: the trailing PE of 37.5 far exceeds the industry average of 16.9, implying overvaluation on a relative basis, while the DCF‑derived fair value of CNY 42.73 dwarfs the current price, flagging deep undervaluation in absolute terms. Revenue growth of 34.7% and robust operating margins (38%) underpin a strong growth narrative, yet the debt‑to‑equity ratio of 130% raises balance‑sheet concerns. The dividend yield is modest at 0.63% with a payout ratio of 22%, indicating that the dividend is likely sustainable given ample cash (CNY 37.7 bn).
Overall, the stock sits at a technical resistance near CNY 4.18, faces a bearish long‑term trend, but offers a compelling upside potential if the DCF assumptions hold and the company can manage its leverage.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price approaching technical resistance at CNY 4.18
  • bearish long‑term SMA200 trend
  • high relative PE versus industry peers

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • significant upside implied by DCF fair value
  • strong revenue growth and operating margins
  • elevated volatility but low beta

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • deep undervaluation relative to DCF estimate
  • sustainable dividend with low payout ratio
  • ample cash reserves to support debt reduction

Key Metrics & Analysis

Financial Health

Revenue Growth34.70%
Profit Margin25.03%
P/E Ratio37.5
ROE3.58%
ROA0.96%
Debt/Equity130.24
P/B Ratio1.3
Op. Cash FlowCN¥7.1B
Industry P/E16.9

Technical Analysis

TrendBearish
RSI57.7
SupportCN¥3.71
ResistanceCN¥4.18
MA 20CN¥3.97
MA 50CN¥4.00
MA 200CN¥4.31
MACDBullish
VolumeIncreasing
Fear & Greed Index90.82

Valuation

Fair ValueCN¥42.73
GradeUndervalued
TypeGrowth
Dividend Yield0.63%

Risk Assessment

Beta0.51
Volatility31.47%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.